231 related articles for article (PubMed ID: 25993269)
1. Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Tang C; Li C; Zhang S; Hu Z; Wu J; Dong C; Huang J; Zhou HB
J Med Chem; 2015 Jun; 58(11):4550-72. PubMed ID: 25993269
[TBL] [Abstract][Full Text] [Related]
2. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
3. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.
Li C; Tang C; Hu Z; Zhao C; Li C; Zhang S; Dong C; Zhou HB; Huang J
Bioorg Med Chem; 2016 Jul; 24(13):3062-3074. PubMed ID: 27240467
[TBL] [Abstract][Full Text] [Related]
5. Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency against Breast Cancer.
Ning W; Hu Z; Tang C; Yang L; Zhang S; Dong C; Huang J; Zhou HB
J Med Chem; 2018 Sep; 61(18):8155-8173. PubMed ID: 30053783
[TBL] [Abstract][Full Text] [Related]
6. Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.
Palermo AF; Diennet M; El Ezzy M; Williams BM; Cotnoir-White D; Mader S; Gleason JL
Bioorg Med Chem; 2018 Aug; 26(15):4428-4440. PubMed ID: 30078609
[TBL] [Abstract][Full Text] [Related]
7. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Ren Y; Li S; Zhu R; Wan C; Song D; Zhu J; Cai G; Long S; Kong L; Yu W
J Med Chem; 2021 Jun; 64(11):7468-7482. PubMed ID: 34043359
[TBL] [Abstract][Full Text] [Related]
8. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Zhang T; Chen Y; Li J; Yang F; Wu H; Dai F; Hu M; Lu X; Peng Y; Liu M; Zhao Y; Yi Z
Neoplasia; 2014 Aug; 16(8):665-77. PubMed ID: 25220594
[TBL] [Abstract][Full Text] [Related]
9. Structural optimization of tetrahydroisoquinoline-hydroxamate hybrids as potent dual ERα degraders and HDAC inhibitors.
Xiong S; Wang X; Zhu M; Song K; Li Y; Yang J; Liu X; Liu M; Dong H; Chen M; Chen D; Xiang H; Luo G
Bioorg Chem; 2023 May; 134():106459. PubMed ID: 36924653
[TBL] [Abstract][Full Text] [Related]
10. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
11. A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Patel HK; Siklos MI; Abdelkarim H; Mendonca EL; Vaidya A; Petukhov PA; Thatcher GR
ChemMedChem; 2014 Mar; 9(3):602-13. PubMed ID: 23956109
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor α antagonism.
Wu J; Yan J; Fang P; Zhou HB; Liang K; Huang J
Cancer Lett; 2020 Jan; 469():78-88. PubMed ID: 31629931
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
[TBL] [Abstract][Full Text] [Related]
16. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
[TBL] [Abstract][Full Text] [Related]
17. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
19. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]